Friday's Health Winners & Losers

Dendreon shares are spiking after the FDA calls its prostate cancer vaccine treatment safe.
Author:
Publish date:

Updated from 12:13 p.m. EDT

Dendreon

(DNDN)

shares soared 147.7% Friday after the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating the disease. A final decision from the FDA is expected on May 15. Shares of Dendreon rose $7.71 to $12.93.

Shares of

Medarex

(MEDX)

also are on the rise. The company said late Thursday that its Valortim drug was effective in the treatment and prevention of anthrax infections when tested on monkeys. The stock closed up $1.45, or 12.6%, to $12.94.

On the flip side,

Acadia Pharmaceuticals

(ACAD) - Get Report

and

AtheroGenics

(AGIX)

, both of which have fluctuated greatly in price over the previous two weeks, moved lower over the course of the day. Acadia fell 9% to close at $15.02. AtheroGenics shed 3.2% to $2.71 in earlier trading but closed up slightly for the day at $2.81.

Among other health care winners Friday,

Cell Genesys

(CEGE)

added 20% to $4.20.

Ligand Pharmaceuticals

(LGND) - Get Report

was up 2.3% to $10.22 earlier in the day and closed at $10.08.

Coventry Health Care

(CVH)

was gaining 1.6% earlier in the day to $56.56 and closed at $56.05.

Other decliners included

Isis Pharmaceuticals

(ISIS)

, which lost 1.7% to $9.27.

Pfizer

(PFE) - Get Report

closed off 0.6% at $25.26, and

Shire

(SHPGY)

fell 1.8% to $61.90.